Brand and Other Names:Oncaspar, PEG L Asparaginase
- Classes: Antineoplastics, Other
Dosing & Uses
Dosage Forms & Strengths
powder for injection
- 750 units (5 mL)
Dosage Forms & Strengths
powder for injection
- 750 units
Acute Lymphoblastic Leukemia
- BSA ≤ 0.6 m²: 82.5 units/kg IM or IV q14Days as part of multiagent chemotherapeutic regimen
- BSA >0.6 m²: 2500 units/m² IM (preferred) or IV q14Days as part of multiagent chemotherapeutic regimen
CBC, serum amylase
Serious - Use Alternative
Significant - Monitor Closely
- Fever, malaise
- Nausea, vomiting
- ALT increased
- Peripheral edema
- CNS toxicity
- Erythema, rash, urticaria
- Hyperglycemia, hyperuricemia, hypoglycemia, hypoproteinemia, hyperlipidemia
- Bleeding tendency
- LFT abnormalities, AST increased, jaundice, hyperbilirubinemia
History of (with prior L-asparaginase treatment): pancreatitis; hemorrhagic events; serious thrombosis
No more than 2 mL should be administered at any one injection site
Anaphylaxis or serious allergic reactions may occur, monitor patient for 1 hr after administration; discontinue with serious allergic reactions
Glucose intolerance reported (irreversible in some cases); monitor serum glucose
Hepatotoxicity and abnormal liver function, including elevations of AST (SGOT), ALT (SGPT), alkaline phosphatase, bilirubin (direct and indirect), and depression of serum albumin, and plasma fibrinogen may occur; monitor
Discontinue if pancreatitis occurs; evaluate patients with abdominal pain for pancreatitis
Serious thrombotic events, including sagittal sinus thrombosis reported; discontinue if this occurs
Increased prothrombin time, increased PTT and hypofibrinogenemia may occur; monitor for coagulopathy
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Modified version of L-asparaginase depletes asparagine, the aminoacid required for protein synthesis, and in turn kills leukemic cells
Half-Life: 5-5.6 days
Onset: Asparagine depleted within 4 days (IM)
Duration: 21 days (IM); 2-4 weeks (IV in asparaginase naive adults)
Vd: 1.5 L/m² (IM in children); 2.4 L/m² (IV in adults)
Peak plasma time: 3-4 days (IM)
Excretion: Urine (trace amounts)
No need for test dose
IM: must only be given as a deep intramuscular injection into a large muscle; limit the volume of a single injection site to 2 mL; if the volume to be administered is >2 mL, use multiple injection sites
IV given as a 1- to 2- hr infusion; do not give IV push
- Have parenteral epinephrine, diphenhydramine, and hydrocortisone available at the bedside
- Have a freely running IV in place
- Have a physician readily accessible
- Monitor the patients closely for 30-60 min
- Do not filter solution
- Have available appropriate agents for maintenance of an adequate airway and treatment of a hypersensitivity reaction (antihistamine, epinephrine, oxygen, IV corticosteroids)
- Be prepared to treat anaphylaxis at each administration
- Administer through an infusion that is already running
Reconstitution: Avoid excessive agitation; do not shake
Standard IM dilution: Do not exceed 2 mL volume per injection site
Standard IV dilution: Dose/100 mL NS or D5W
Do not use if cloudy or if precipitate is present
Do not freeze
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs